Lidokain/Adrenalin Aguettant (Epinephrine, Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels, stopping nerve impulse transmission and producing numbness. Epinephrine stimulates alpha‑adrenergic receptors, causing vasoconstriction that limits systemic absorption of lidocaine, thereby extending its duration of action and minimizing intra‑operative bleeding.

The specific dose and concentration are determined by the prescribing clinician based on the procedure, patient weight, and clinical guidelines. Healthcare professionals calculate the appropriate volume to stay within recommended maximum lidocaine limits and consider epinephrine concentration for safety.

Safety data for Lidokain/Adrenalin Aguettant in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with plain lidocaine solutions, the addition of epinephrine prolongs anesthesia, reduces systemic absorption, and decreases bleeding. Unlike some newer agents, this combination is well‑established, cost‑effective, and widely used for a variety of regional techniques, though it shares similar toxicity thresholds.

Lidokain/Adrenalin Aguettant should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the solution from direct sunlight, moisture, and extreme temperatures. Do not freeze; inspect for particulate matter before use.

The sterile solution is administered by a qualified healthcare professional via injection. Routes include epidural, infiltration, intravenous, or perineural administration, depending on the clinical indication and procedural requirements. Proper aseptic technique and dosage calculation are essential.

Serious adverse events include anaphylaxis, severe cardiac arrhythmias, seizures, and methemoglobinemia. Immediate medical attention is required if patients develop signs of allergic reaction, profound cardiovascular instability, or neurologic symptoms after administration.

Patients with known hypersensitivity to lidocaine, epinephrine, or any component of the formulation should avoid this product. It is also contraindicated in individuals with uncontrolled hypertension, certain cardiac conduction disorders, or those taking non‑selective MAO inhibitors.